Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dx Departure: US FDA's Diagnostics Chief Gutierrez Steps Down

Executive Summary

Alberto Gutierrez left FDA and government this week in a planned retirement. He was director of the office that oversees pre- and post-market programs for in vitro diagnostics and radiology devices, an office where several holes already exist in top management slots.

You may also be interested in...



Molecular Dx Exec Named New US FDA Diagnostics Chief

Timothy Stenzel brings experience developing and commercializing new molecular diagnostics, including companion tests, and running a clinical laboratory to his new role as director of US FDA's Office of In Vitro Diagnostics and Radiological Health.

The Meaning Of 'Accurate': Debate Continues With Latest CLIA Waiver Guidances

Accuracy "is a widely used and generally understood term in clinical laboratory sciences," according to US FDA, but industry groups say the agency continues to misunderstand Congress' use of the word when it comes to CLIA waivers for point-of-care tests, including in a draft guidance document issued by the agency in recent days. FDA is also touting a new, more efficient approach to dual 510(k)-CLIA waiver submissions. 

Abbott Gains Go-Ahead For First 'No-Fingerstick' CGM

Abbott Laboratories' Freestyle Libre Flash is the first continuous glucose monitoring system to gain US FDA approval that lets diabetics avoid the additional step of fingerstick calibration to measure their glucose levels, "with the wave of a mobile reader," the agency says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT121561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel